INVITATION
AstraZeneca - Improving outcomes with immuno-oncology: Evolving treatment paradigms for first-line ES-SCLC and unresectable stage III NSCLC
INVITATION
MSD - Extending Longer-Term Survival in Lung Cancer and HNSCC with IO and Novel Combinations
INVITATION
AstraZeneca - Improving patient outcomes in early-stage and advanced EGFR-mutant NSCLC: Emerging strategies
INVITATION
Pfizer - Beyond 2020: Targeting EGFR Exon 19 and Exon 21 L858R in the New Era
INVITATION
Boehringer Ingelheim - Targeting the undruggable in KRAS-mutated advanced NSCLC and mCRC
INVITATION
Boehringer Ingelheim - Treatment considerations for advanced NSCLC: Now and in the future
